• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    SC 13D/A 1 schedule13da.htm SCHEDULE 13D/A


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13D
    (Rule 13d-101)

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)

    National Research Corporation
    __________________________________________________________________________________
    (Name of Issuer)

    Common Stock, $.001 par value
    __________________________________________________________________________________
    (Title of Class of Securities)

    637372202
    __________________________________________________________________________________
    (CUSIP Number)

    Thomas Richardson
    Arnold & Porter Kaye Scholer LLP
    601 Massachusetts Ave., NW
    Washington, D.C. 20001-3743
    202-942-5171
    __________________________________________________________________________________
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 1, 2024
    __________________________________________________________________________________
    (Date of Event Which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [  ]
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).


    CUSIP NO.:  637372202

    1.
    Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
     
    Thomas Richardson, as the Trustee of Common Property Trust and as Manager of Common Property Trust LLC
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) [   ]
    (b) [   ]
    3.
    SEC USE ONLY
     
    4.
    Source of Funds (See Instructions)
    OO
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    [   ]
    6.
    Citizenship or Place of Organization
     
    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person with
    7.
    Sole Voting Power
    3,854,284
     
    8.
    Shared Voting Power
    0
     
     
    9.
    Sole Dispositive Power
    3,854,284
     
     
    10.
    Shared Dispositive Power
    0
     
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    3,854,284
     
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    [    ]
    13.
    Percent of Class Represented by Amount in Row (11)
    16.2%(1)
     
    14.
    Type of Reporting Person (See Instructions)
    IN
     

     
    (1)
    The percentage indicated is based upon 23,854,428 shares of common stock outstanding as of February 13, 2024, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on February 27, 2024.

    CUSIP NO.:  637372202

    1.
    Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
     
    Common Property Trust
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) [   ]
    (b) [   ]
    3.
    SEC USE ONLY
     
    4.
    Source of Funds (See Instructions)
    OO
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    [   ]
    6.
    Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person with
    7.
    Sole Voting Power
    3,854,284
     
    8.
    Shared Voting Power
    0
     
     
    9.
    Sole Dispositive Power
    3,854,284
     
     
    10.
    Shared Dispositive Power
    0
     
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    3,854,284
     
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    [    ]
    13.
    Percent of Class Represented by Amount in Row (11)
    16.2%(1)
     
    14.
    Type of Reporting Person (See Instructions)
    OO
     

     
    (1)
    The percentage indicated is based upon 23,854,428 shares of common stock outstanding as of February 13, 2024, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on February 27, 2024.


    CUSIP NO.:  637372202

    1.
    Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
     
    Common Property Trust LLC (85-3188822)
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) [   ]
    (b) [   ]
    3.
    SEC USE ONLY
     
    4.
    Source of Funds (See Instructions)
    OO
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    [   ]
    6.
    Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person with
    7.
    Sole Voting Power
    3,854,284
     
    8.
    Shared Voting Power
    0
     
     
    9.
    Sole Dispositive Power
    3,854,284
     
     
    10.
    Shared Dispositive Power
    0
     
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    3,854,284
     
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    [    ]
    13.
    Percent of Class Represented by Amount in Row (11)
    16.2%(1)
     
    14.
    Type of Reporting Person (See Instructions)
    OO
     

     
    (1)
    The percentage indicated is based upon 23,854,428 shares of common stock outstanding as of February 13, 2024, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on February 27, 2024.

    CUSIP NO.:  637372202

    Item 1.
    Security and Issuer.

    This Amendment No. 1 to Schedule 13D, which relates to shares of the Common Stock, par value $.001 per share (the “Common Stock”), of National Research Corporation, a Delaware corporation (the “Issuer”), is being filed on behalf of Thomas Richardson, as Trustee of Common Property Trust and as Manager of Common Property Trust LLC (the “Trustee”),  Common Property Trust (the ”Trust”), and Common Property Trust LLC (“CPT LLC”) to amend the Reporting Persons’ Schedule 13D, as amended (the “Schedule 13D”), originally filed on March 22, 2021.  Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the same meanings as set for in the Schedule 13D.  The address of the principal executive offices of the Issuer is 1245 Q Street, Lincoln, Nebraska 68508.

    Item 5.
    Interest in Securities of the Issuer.

    (a) Set forth below is the aggregate number and percentage of outstanding shares of Common Stock owned beneficially by each Reporting Person named in Item 2 (based on 23,854,428 shares of Common Stock outstanding as of February 13, 2024):

    Name
    Shares of Common Stock
    Beneficially Owned
    Percentage of Shares of Common Stock Beneficially Owned
    Trustee, the Trust, and CPT LLC
    Common Stock –3,854,284
    16.2%

    CPT LLC directly owns 3,854,284 shares of Common Stock and has sole voting and dispositive power over such shares.  The Trust owns all of the equity interests of CPT LLC.  The Trustee is the trustee of the Trust and is the manager of CPT LLC.  Accordingly, the Trustee and the Trust may be deemed to have sole voting and dispositive power with regard to the shares of Common Stock held by CPT LLC and the Trustee may be deemed to have sole voting and dispositive power with regard to shares of Common Stock held by the Trust.

    (b) The Trustee has sole voting and dispositive power of the Common Stock beneficially owned by the Trust and CPT LLC for reasons described in Item 5(a).

    (c) The following transactions in the Common Stock have occurred during the past 60 days by the Reporting Persons:

    Name
    Trade Date
    Number of Shares
    Price Per Share
    Where and How Transaction was Effected
    Trustee, the Trust, and CPT LLC
    03/01/2024
    598,653
    $40.54
    Private sale

    (d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock beneficially owned by any Reporting Person.

    (e) Not applicable.



    Item 7.
    Material to be Filed as Exhibits.
     
     
    Exhibit 99.1
    Joint Filing Agreement, dated March 18, 2021, by and among Common Property Trust, Common Property Trust LLC, and Thomas Richardson as Trustee of Common Property Trust and Manager of Common Property Trust LLC (incorporated by reference to Exhibit 99.1 of the Schedule 13D filed with the Securities and Exchange Commission on March 22, 2021).
     
    Exhibit 99.2
    Purchase Agreement, dated March 11, 2021, by and between Bessemer Trust Company of Delaware, N.A., as Trustee of the K/I/E Trust Under Agreement dated October 24, 2018, and Common Property Trust LLC, a Delaware limited liability company (incorporated by reference to Exhibit 99.2 of the Schedule 13D filed with the Securities and Exchange Commission on March 22, 2021).
     
    Exhibit 99.3
    Promissory Note issued by Common Property Trust LLC, in favor of Bessemer Trust Company of Delaware, N.A., as Trustee of the K/I/E Trust under agreement dated October 24, 2018 (incorporated by reference to Exhibit 99.3 of the Schedule 13D filed with the Securities and Exchange Commission on March 22, 2021).
     
    Exhibit 99.4
    Guaranty of Amandla LLC, dated March 11, 2021 (incorporated by reference to Exhibit 99.4 of the Schedule 13D filed with the Securities and Exchange Commission on March 22, 2021).
     
    Exhibit 99.5
    Power of Attorney of Common Property Trust and Thomas Richardson as Trustee of Common Property Trust (incorporated by reference to Exhibit 99.5 of the Schedule 13D filed with the Securities and Exchange Commission on March 22, 2021).
     
    Exhibit 99.6
    Power of Attorney of Common Property Trust LLC and Thomas Richardson as Manager of Common Property Trust LLC (incorporated by reference to Exhibit 99.6 of the Schedule 13D filed with the Securities and Exchange Commission on March 22, 2021).
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.
     
     
    Thomas Richardson, as Trustee of the Common Property Trust
     
         
         
     
    /s/ Thomas Richardson, by Heidi Hornung-Scherr, attorney-in-fact, pursuant to a Power of Attorney previously filed with the SEC
     
         
         
     
    COMMON PROPERTY TRUST, by Thomas Richardson, as Trustee
     
         
         
     
    /s/ Thomas Richardson, by Heidi Hornung-Scherr, attorney-in-fact, pursuant to a Power of Attorney previously filed with the SEC
     

     
    Thomas Richardson, as Manager of Common Property Trust LLC
     
         
         
     
    /s/ Thomas Richardson, by Heidi Hornung-Scherr, attorney-in-fact, pursuant to a Power of Attorney previously filed with the SEC
     
         
         
     
    COMMON PROPERTY TRUST LLC, by Thomas Richardson, as Trustee
     
         
         
     
    /s/ Thomas Richardson, by Heidi Hornung-Scherr, attorney-in-fact, pursuant to a Power of Attorney  previously filed with the SEC
     

    Dated: March 5, 2024

    Get the next $NRC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Green Trent S was granted 500,000 shares (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      6/3/25 4:47:16 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 3 filed by new insider Green Trent S

      3 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      6/3/25 4:41:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • A New Era of Trust: NRC Health's 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience

      NRC Health unveils its 2025 Experience Perspective Report, highlighting new research and trends shaping the future of healthcare, with a focus on trust, generational shifts, and evolving consumer demands. NRC Health, a recognized leader in healthcare experience management solutions to transform interactions for patients, consumers, and employees alike, released its 2025 Experience Perspective today during a live national webcast. Known for delivering premier market research and data-driven insights, NRC Health's report features key findings and strategic recommendations based on extensive research involving millions of consumers, patients, and other healthcare leaders nationwide. Guided b

      4/10/25 2:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Financials

    Live finance-specific insights

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Announces Fourth Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $58.5 million. Total recurring contract value (TRCV) was approximately $133.2 million at December 31, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $10.1 millio

      1/27/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    SEC Filings

    See more
    • National Research Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/12/25 9:01:47 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by National Research Corporation

      10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/9/25 10:02:32 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      4/28/25 5:12:02 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    See more
    • National Research Corporation Appoints Trent Green as Chief Executive Officer

      National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

      3/4/25 4:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer

      Baron will align and advance NRC Health's experience solutions platform to solve health care industry challenges and continue effectively innovating and supporting experience improvement for health systems across the nation. NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho

      4/2/24 11:55:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

      NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions. The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners. Four newly created executive leadership roles will guide NRC Health's strategy and success, including: Helen Hrdy, Chief Customer Officer Jason Hahn, Chief Revenue Officer Christophe Louvion, Chief Product Technology Officer Andy Monnich, Chief Corporate Development Officer "Strong leadership is key in driving innovation and meeting the ever-evolv

      2/1/24 10:00:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Research Corporation

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      11/13/24 4:05:19 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by National Research Corporation (Amendment)

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/8/24 4:05:05 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by National Research Corporation (Amendment)

      SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/5/24 4:31:31 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care